Fabiana Perna,Manuel R Espinoza-Gutarra,Giuseppe Bombaci et al.
Fabiana Perna et al.
Acute myeloid leukemia (AML) is an aggressive, clonally heterogeneous, myeloid malignancy, with a 5-year overall survival of approximately 27%. It constitutes the most common acute leukemia in adults, with an incidence of 3-5 cases per 100,...
Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution [0.03%]
泌尿生殖系统肿瘤的免疫治疗：渐变还是突变？
Kevin Lu,Kun-Yuan Chiu,Chen-Li Cheng
Kevin Lu
Immunotherapy, the 5th pillar of cancer care after surgery, radiotherapy, cytotoxic chemotherapy, and precision therapy (molecular targeted therapy), is revolutionizing the standard of care in certain patients with genitourinary malignancie...
Francesca Aroldi,Reem Saleh,Insiya Jafferji et al.
Francesca Aroldi et al.
The introduction of immune checkpoint inhibitors represented a breakthrough treatment for metastatic melanoma, but the effect of these agents is not limited to a single cancer type. Promising results have been reported in various solid tumo...
Amitesh Verma,Sarwish Rafiq
Amitesh Verma
Genetic modification of T cells to express chimeric antigen receptors (CARs) has yielded remarkable clinical outcomes and initiated a novel era for cancer immunotherapy. The impressive clinical responses seen in hematologic malignancies hav...
Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer [0.03%]
具有同种异体肿瘤抗原特异性的T细胞用于癌症的广泛适用性过继性细胞疗法
Zaki Molvi,Richard J O&#x;Reilly
Zaki Molvi
T cells specific for major histocompatibility complex (MHC)-presented tumor antigens are capable of inducing durable remissions when adoptively transferred to patients with refractory cancers presenting such antigens. When such T cells are ...
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity [0.03%]
激活实体肿瘤中的模式识别受体以产生全身性抗肿瘤免疫反应
Michael Brown
Michael Brown
Malignant tumors frequently exploit innate immunity to evade immune surveillance. The priming, function, and polarization of antitumor immunity fundamentally depends upon context provided by the innate immune system, particularly antigen pr...
Vishal Navani,Moira C Graves,Hiren Mandaliya et al.
Vishal Navani et al.
Melanoma gave science a window into the role immune evasion plays in the development of malignancy. The entire spectrum of immune focused anti-cancer therapies has been subjected to clinical trials in this disease, with limited success unti...
Diana C DeLucia,John K Lee
Diana C DeLucia
Cancer immunotherapy, or the utilization of components of the immune system to target and eliminate cancer, has become a highly active area of research in the past several decades and a common treatment strategy for several cancer types. Th...
Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL) [0.03%]
嵌合抗原受体(CAR)T细胞治疗B细胞性急性淋巴性白血病(B-ALL)
Geoffrey Shouse,Elizabeth Budde,Stephen Forman
Geoffrey Shouse
With the exploitation of adoptive immunotherapies, the outcomes of patients with relapsed and refractory B cell hematologic malignancies have seen drastic improvements. To this end, a paradigm shift away from toxic and ineffective chemother...
Sheeja T Pullarkat,Winnie Wu,Vinod Pullarkat
Sheeja T Pullarkat
Mastocytosis is a rare hematologic disorder characterized by abnormal proliferation and accumulation of neoplastic mast cells in various body sites. Isolated skin involvement is termed cutaneous mastocytosis (CM) and the term systemic masto...